Effects of tapering tumor necrosis factor inhibitor on the achievement of inactive disease in patients with axial spondyloarthritis: a nationwide cohort study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Jun Won | - |
dc.contributor.author | Kim, Hyoun-Ah | - |
dc.contributor.author | Shin, Kichul | - |
dc.contributor.author | Park, Yong-Beom | - |
dc.contributor.author | Kim, Tae-Hwan | - |
dc.contributor.author | Song, Yeong Wook | - |
dc.contributor.author | Lee, Eun Young | - |
dc.date.accessioned | 2021-08-02T11:28:22Z | - |
dc.date.available | 2021-08-02T11:28:22Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2019-07 | - |
dc.identifier.issn | 1478-6354 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/13374 | - |
dc.description.abstract | Objectives To investigate the association between the extent of tapering tumor necrosis factor inhibitor (TNFi) and the likelihood of achieving inactive disease in patients with axial spondyloarthritis (axSpA) Methods We analyzed 1575 1-year follow-up interval data of 776 axSpA patients treated with TNFi for more than 1 year in a nationwide observational cohort. The decision on tapering TNFi was made by patients and their physicians. We quantified TNFi used during interval as a dose quotient (DQ). The intervals were classified into the heavy-tapering (DQ < 50), mild-tapering (DQ 50–99), and control groups (DQ = 100). Outcome variables included achieving Ankylosing Spondylitis Disease Activity Score-inactive disease (ASDAS-ID) and major clinical response of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI50) in the follow-up visit. The effects of TNFi tapering on the outcome were analyzed using the generalized estimating equation. Results At the baseline visit, 91.1% of the patients showed a high disease activity (ASDAS-CRP ≥ 2.1). DQ of each interval was significantly influenced by the ASDAS-CRP measure in the prior follow-up (P < 0.001). ASDAS-ID was observed in 42.3% of the intervals. A multivariable analysis showed that the likelihood of outcome achievement was comparable between the control and mild-tapering groups, but significantly decreased in the heavy-tapering group (vs. the control group, adjusted OR = 0.28, [95% CI, 0.08–0.94]). In contrast, the likelihood to achieve BASDAI50 response was not different among the groups. In the subgroup of patients who reached ASDAS-ID 1 year after TNFi treatment (n = 327), ASDAS-ID was observed in 66.1% of the subsequent intervals, and only the mild-tapering group showed a likelihood of target maintenance comparable with that of the control group (adjusted OR = 1.25 [0.41–3.80]). This likelihood decreased with an increase in ASDAS-CRP. Conclusion Mild tapering of TNFi has efficacy comparable with that of the standard-dose treatment for ASDAS-ID achievement in patients with axSpA. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | BMC | - |
dc.title | Effects of tapering tumor necrosis factor inhibitor on the achievement of inactive disease in patients with axial spondyloarthritis: a nationwide cohort study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Tae-Hwan | - |
dc.identifier.doi | 10.1186/s13075-019-1943-6 | - |
dc.identifier.scopusid | 2-s2.0-85068599155 | - |
dc.identifier.wosid | 000474362800001 | - |
dc.identifier.bibliographicCitation | ARTHRITIS RESEARCH & THERAPY, v.21, no.1 | - |
dc.relation.isPartOf | ARTHRITIS RESEARCH & THERAPY | - |
dc.citation.title | ARTHRITIS RESEARCH & THERAPY | - |
dc.citation.volume | 21 | - |
dc.citation.number | 1 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Rheumatology | - |
dc.relation.journalWebOfScienceCategory | Rheumatology | - |
dc.subject.keywordPlus | FACTOR-ALPHA INHIBITOR | - |
dc.subject.keywordPlus | ANTI-TNF THERAPY | - |
dc.subject.keywordPlus | ANKYLOSING-SPONDYLITIS | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | CLINICAL-RESPONSE | - |
dc.subject.keywordPlus | REMISSION | - |
dc.subject.keywordPlus | PREDICTORS | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordPlus | MULTICENTER | - |
dc.subject.keywordAuthor | Spondyloarthritis | - |
dc.subject.keywordAuthor | Tumor necrosis factor | - |
dc.subject.keywordAuthor | Dose tapering | - |
dc.subject.keywordAuthor | Inactive disease | - |
dc.identifier.url | https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-019-1943-6 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.